1. Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome.
- Author
-
Plasse, Richard A, Nee, Robert, and Olson, Stephen W
- Subjects
- *
ALISKIREN , *CHRONIC kidney failure , *ANTIHYPERTENSIVE agents , *COMPLEMENT activation , *SYNDROMES - Abstract
Direct renin inhibitors (DRIs) block the activation of the alternative complement pathway in vitro and could be a treatment option for refractory hypertension in atypical hemolytic uremic syndrome (aHUS). A 20-year-old male presented with primary aHUS complicated by end-stage renal disease and refractory malignant hypertension despite being on five antihypertensive medications at maximum dose. Only a partial response was achieved with aliskiren and eculizumab, but after increasing aliskiren to a supratherapeutic dose, antihypertensive medication was reduced, platelets increased, C3 increased and epoetin alfa requirement decreased. DRI may be an adjunct treatment for malignant hypertension associated with aHUS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF